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1. Introduction
Prodrugs are inactive precursors of an active drug designed to
be bioconverted (activated) post administration with the main
aim of improving the pharmacokinetic properties of the par-
ent drug. Prodrugs have been successful for a longtime.
Sulfasalazine, one of the earliest prodrugs, reaches the colon
and is metabolized by bacteria into two active metabolites:
sulfapyridine and 5-aminosalicylic acid (5-ASA). Sulfasalazine
was approved for use in the USA in 1950 and still is considered
first-line treatment in autoimmune conditions such as Crohn’s
disease and ulcerative colitis [1]. It has been demonstrated
that the prodrug approach has reached vast success in the
past few years. It is estimated that around 10% of all marketed
drugs are prodrugs, 20% of small molecular weight drugs
approved between 2000 and 2008 were prodrugs, and
between 2008 and 2017 the share of prodrugs in the drug
market was 12% [2].
Various strategies are employed in the prodrug approach.
The most common of which is making a prodrug susceptible
to abundant enzymes by functionalization with a group that
can be cleaved to produce the active form of the drug. The
prodrug approach to drug optimization offers chemical stabi-
lity such as an inactive oral prodrug can be stable in the
gastrointestinal tract and only be bioconverted by CYP450 in
the liver, plasma, or GIT mucosal esterase, or other enzymes.
Examples of this include phosphate groups which are suscep-
tible to alkaline phosphatase, ester groups which are suscep-
tible to esterases, and carbamates or amidine groups which
are susceptible to amidases. Newer strategies include pegyla-
tion, which is used to increase cellular uptake, and dimer
prodrugs, which are cleaved to two active moieties.
Also, prodrugs can be used as precursors in biological
conversion pathways, as is the case with L-dopa, a prodrug
of dopamine. L-dopa crosses the blood-brain barrier through
L-type amino acid transporter-1 and is metabolized by aro-
matic amino acid decarboxylase to active dopamine in the
CNS. Targeted prodrugs have also been explored in oncology
in order to minimize side effects and improve the tolerability
of chemotherapy [3].
Prodrugs are also used to increase the duration of action of
medicines, acting as chemical sustained release forms.
Lisdexamfetamine dimesylate is an inactive prodrug of
amphetamine used mainly in the treatment of attention deficit
hyperactivity disorder (ADHD). The prodrug is hydrolyzed by
red blood cells to L-lysine and active d-amphetamine. The
duration of action of lisdexamfetamine is 12 h [4] compared
to that of instant release amphetamine, which is 3-6 h.
In cardiovascular medicine, prodrugs have been successful.
Older prodrugs such as angiotensin-converting enzyme inhi-
bitors (ACEi) are considered cornerstones in the management
of hypertension. ACE inhibitors are dicarboxyl ester prodrugs
converted to their active -rilat form by liver esterase (such as
enalapril and enalaprilat). The exceptions for this are lisinopril
and captopril which are not prodrugs, and fosinopril, which is
a phosphonic acid prodrug hydrolyzed by liver and GIT
mucosa esterases. Newer prodrugs, such as dabigatran etex-
ilate and prasugrel (Table 1), are anticoagulants indicated for
the treatment and prevention of blood clotting.
Prodrugs of nucleoside analogs are used to improve phar-
macokinetic properties such as intestinal permeability and oral
absorption [15]. For instance, valacyclovir and valganciclovir
are valine ester prodrugs of acyclovir and ganciclovir, respec-
tively, target intestinal oligopeptide transporter aiming to
improve the oral absorption of the parent drug.
2. Continued need for prodrugs
During the years 2008–2017, a total of 249 new molecular
entities were approved, 31 of which were prodrugs. With the
exception of 2016, which had no novel drug approvals of
prodrugs, and 2012, which had one, each year at least 2
approvals of prodrugs were reported. Table 1 summarizes
novel prodrugs granted FDA approval during 2008–2018.
While the majority of the prodrugs mentioned above are
hydrolyzed by esterases; romidepsin, sofosbuvir, benznidazole,
and secnidazole reach the intracellular environment as inactive
entities. Romidepsin is a novel anticancer agent. It is activated by
intracellular glutathione by cleavage of a disulfide bond and
producing a thiol group. This group then binds to a zinc atom in
Zn-dependent histone deacetylase.
Sofosbuvir is a novel and promising antiviral medication
indicated for the treatment of hepatitis C and is used heavily
in combination therapy. Sofosbuvir is a substrate for cathepsin
A and carboxylesterase 1, which metabolize it by removing its
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Table 1. Chemical structures of prodrugs to gain FDA approval during 2008–2018. Some of the listed prodrugs were cited in reference [2].
Year Tradename Prodrug Active form Activation mechanism Prodrug strategy/gain Indication/use
2008 [5] Toviaz Fesoterodine
fumarate
5-hydroxymethyl tolterodine Hydrolysis by nonspecific
esterase
● Avoid variability in
CYP2D6 activity.
Overactive bladder
Lusedra Fospropofol
disodium
Propofol Conversion by alkaline
phosphatase
● Increased aqueous
solubility for IV
injection by
phosphorylation
Anaesthesia
Emend Fosaprepitant
dimeglumine
Aprepitant Dephosphorylation by
phosphatase
● Increased aqueous
solubility by
phosphorylation.
Prevention of
chemotherapy
induced nausea
and vomiting
2009 [6] Effient Prasugrel R-138727 2 steps:
(1) Hydrolysis by esterase.
(2) CYP450 metabolism
● Faster and more
efficient conversion
of parent molecule
compared to
Clopidogrel.
● Increased potency.
Prevention and
reduction of
thrombotic and
cardiovascular
events
Istodax Romidepsin Metabolite with free thiol group Activation by intracellular
glutathione
- Cutaneous T-cell
lymphoma
2010 [7] Gilenya Fingolimod fingolimod-phosphate Phosphorylation by
sphingosine kinase
● Structure activity
relationship based
design to optimize
activity.
Multiple sclerosis
Pradaxa Dabigatran
etexilate
Dabigatran Hydrolysis by esterase ● Structure activity
relationship based
design to optimize
activity.
Thromboembolism
Teflaro Ceftaroline
fosamil
Ceftaroline Plasma phosphatase ● N-phosphono-
prodrug to improve
aqueous solubility.
Acute bacterial skin
and skin structure
infections and
community
acquired
pneumonia
2011 [8] Edarbi Azilsartan
medoxomil
Azilsartan Hydrolysis by esterase during
absorption
- Hypertension
Horizant Gabapentin
enacarbil
Gabapentin Hydrolysis by esterase ● Transport by
intestinal
monocarboxylate
transporter type 1
and sodium
dependent
multivitamin
transporter.
● Hydrolysis in tis-
sues.
Restless leg
syndrome and
post-herpetic
neuralgia
Zytiga Abiraterone
acetate
Abiraterone sulfate and N-oxide
abiraterone sulfate
2 steps:
(1) Hydrolysis by esterase
(2) Metabolism CYP3A4 and
SULT2A1
- Hormone refractory
prostate cancer
2012 [9] Zioptan Tafluprost Tafluprost acid Hydrolysis by esterase ● Good corneal
penetration.
● Better activity
● Lesser pigmentation
Glaucoma
2013 [10] Tecfidera Dimethyl
fumarate
Monomethyl fumarate Hydrolysis by esterase - Multiple sclerosis
Sovaldi Sofosbuvir GS-461203 Intracellular metabolism by:
(1) Cathepsin-
Acarboxylesterase 1
(2) Histidine triade nucleo-
tide-binding protein 1
(3) Uridine monophosphate-
cytidine monophosphate
kinase.
● Phosphoramidate
prodrug to bypass
first step
phosphorylation
required by
nucleoside analogs.
Hepatitis C infection
Aptiom Eslicarbazepine
acetate
Eslicarbazepine Hydrolysis during first pass
metabolism
● Avoid the formation
of epoxide
following
metabolism.
Epilepsy
(Continued )
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terminal ester and phenyl. Finally, phosphorylation by uridine
monophosphate-cytidine monophosphate kinase leads to the
active GS-461203. While the structures of these drugs do not
resemble those of drugs susceptible to tissue and plasma
esterases their affinity to intracellular enzymes made them
prime prodrugs exhibiting targeted pharmacological action.
Table 1. (Continued).
Year Tradename Prodrug Active form Activation mechanism Prodrug strategy/gain Indication/use
2014 [11] Northera Droxidopa Norepinephrine Decarboxylation by
L-aromatic-amino-acid
decarboxylase
- Neurogenic
orthostatic
hypotension and
intradialytic
hypotension
Parkinson’s disease
(off-label)
Sivextro Tedizolid
phosphate
Tedizolid Dephosphorylation by plasma
phosphatase
Structure activity
relationship design.
● Increased monoa-
mineoxidase inhibi-
tory profile.
● Improved aqueous
solubility.
● Improved bioavail-
ability
Acute bacterial skin
and skin infections
2015 [12] Aristada Aripiprazole
lauroxil
Aripiprazole 2 steps:
(1) Hydrolysis by esterase
(2) Non-enzymatic hydrolysis
● Increase lipid
solubility
● Prolonged action
for IM injection.
Schizophrenia
Xuriden Uridine triacetate Uridine Deacetylation by esterase ● Catabolism
resistance
● Enhanced absorp-
tion
Hereditary orotic
aciduria
Entresto Sacubitril LBQ657 De-ethylation by liver
carboxylesterase 1
- Heart failure
Ninlaro Ixazomib citrate Active boronic form Rapid hydrolysis post
administration
● Improved affinity Multiple myeloma
Cresemba Isavuconazonium
sulfate
Isavuconazole 2 steps:
(1) Hydrolysis by esterase
(2) Intramolecular cyclization
leading to N-dealkylation
● Improved aqueous
solubility
Invasive aspergillosis
and invasive
mucormycosis
Genvoya
Odefsey
Descovy
Tenofovir
alafenamide
Tenofovir Hydrolysis by lysosomal
protective protein or liver
carboxylesterase 1
● Phosphoramidate
prodrug.
● Increased lipophili-
city
HIV
Uptravi Selexipag ACT-333679 (MRE-269) Hydrolysis by carboxylesterase ● Improved
bioavailability
Pulmonary arterial
hypertension
2016 [13]
Emflaza Deflazacort 21-desacetyldeflazacort Hydrolysis by esterase - Duchenne muscular
dystrophy
Xermelo Telotristat ethyl Lp-778902 Hydrolysis by carboxylesterase ● Improved
bioavailability
Carcinoid syndrome
diarrhoea
2017 [14] Austedo Deutetrabenazine Mainly
α-dihydrotetrabenazine and β-
dihydrotetrabenazine
CYP450 metabolism ● Deuterated to
retard hepatic
metabolism
Ingrezza Valbenazine
tosylate
Mainly
α-dihydrotetrabenazine
CYP450 metabolism ● Improved
pharmacokinetics
Tardive dyskinesia
Benznidazole Benznidazole Various electrophilic metabolites Reduction by Trypanosoma
cruzinitroreductase
- Chagas disease
Solosec Secnidazole (Active metabolite) Reduction by bacterial
nitroreductase
- Bacterial vaginosis
Vyzulta Latanoprostene
bunod
Latanoprost acid
Butanediol mononitrate
Hydrolysis by corneal esterase ● Good corneal
penetration
● Delivery of NO
releasing species
Glaucoma
2018 Xofluza Baloxavir
marboxil
S-033447 Hydrolysis by esterase - Influenza A and B
Krintafel Tafenoquine 5,6 ortho-quinone tafenoquine Bioconversion by CYP2D6 - Malaria
Akynzeo Fosnetupitant netupitant Dephosphorylation by plasma
phosphatase
● Phosphorylation for
IV injection
Chemotherapy
induced nausea
and vomiting
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Interestingly, latanoprostene bunod (1 in Figure 1) delivers
two active agents in a 1:1 ratio. Upon hydrolysis, the prodrug
releases latanoprost acid, a prostaglandin F2-alpha analog,
and butanediol mononitrate which undergoes further meta-
bolism to NO leading to vascular relaxation. Hence, this pro-
drug acts via a dual mechanism which leads to lowering of the
intraocular pressure.
Although the prodrug approach is advancing and reaching
successes in providing effective medications to a variety of
diseases it still needs the utilization of the sophisticated com-
putational methods used for the design of drugs. Kinetics and
thermodynamics for biological systems (active sites of recep-
tors and enzymes, and etc.) that have biomedicinal interests
have been intensively researched and have been proved to be
fruitful. Today, quantum mechanics, such as ab initio, semi-
empirical, and density functional theory (DFT), and molecular
mechanics (MM) including docking are increasingly being uti-
lized to characterize active sites of receptors and enzymes.
These widely used methods have proven as successful tools
for providing structure-energy calculations for an accurate
prediction of potential drugs [16].
3. Expert opinion
The strategies and aims of prodrugs to be approved in the
past decade are reported in Table 1. Phosphorylation to
improve aqueous solubility was successfully used in the
design of fospropofol, fosaprepitant, and fosnetupitant allow-
ing for injections. On the other hand, gabapentin enacarbil
was designed to increase the bioavailability of gabapentin by
targeting intestinal transporters monocarboxylate transporter
type 1 and sodium-dependent multivitamin transporter.
Prodrugs can also be designed to overcome metabolic
drawbacks. Tolterodine and fesoterodine are both indicated
for overactive bladder disease and both metabolized to
5-hydroxymethyl tolterodine. The bioactivation of tolterodine
is highly dependent on CYP2D6 activity which resulted in
interpatient variability. Fesoterodine, on the other hand, is
rapidly and completely hydrolyzed by non-specific esterases.
Also, eslicarbazepine acetate solved the problem of its prede-
cessors: carbamazepine and oxcarbazepine which produced
toxic metabolites such as epoxides.
Taking a leaf from the book of sofosbuvir, the design of
prodrugs with the aim of intracellular bioconversion rather
than the classical approach to amidase, esterase, or CYP450
activation would be beneficial in the treatment of conditions
such as viral infections, cancers, and in the revolution of future
antibiotics.
As per November 2018, three prodrugs have been
approved; tafenoquine, and fosnetupitant. Baloxavir marboxil
(2 in Figure 1) is a novel agent with a novel mechanism of
action. It is indicated for the treatment of influenza A and
B and given as a single dose during the first 48 h hours of
influenza symptoms. It inhibits viral shedding through the
inhibition of viral CAP endonuclease. Tafenoquine (3 in
Figure 1) is an 8-aminoquinoline analog of primaquine indi-
cated for the treatment of malaria. Fosnetupitant (4 in Figure
1) is the prodrug form of netupitant and one of the active
ingredients in Akynzeo, a drug approved for the treatment of
acute and delayed nausea due to chemotherapy. It is depho-
sphorylated by plasma phosphatase to produce the active
form.
While current trends point toward an age of biological
treatments such as antibodies, prodrugs still prove viable
products. I believe that the prodrug approach has a strong
potential to grow rapidly in such a way that it will provide
more than 25% of the marketed therapeutics during the com-
ing decade if the researchers in the field utilize the computa-
tional methods used in the drug design and discovery.
Computational methods based on quantum mechanics
and MM could be used for the design of prodrugs. Prodrugs
targeting transporters could be designed with the assistance
of computational methods such as docking and etc. In
a similar way, prodrugs targeting esterases, amidases and,
Figure 1. Chemical structures of latanoprostene bunod (1), baloxavir marboxil (2), tafenoquine (3), and fosnetupitant (4).
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etc., can be more effective if their design is relied on DFT and
ab-inito methods that they have a great ability to predict
kinetics of chemical systems. In our group we have used DFT
methods for unraveling mechanisms of intramolecular pro-
cesses that were previously studied in the labs of others to
comprehend enzyme catalysis. Our goal was to establish
a correlation between experimental and calculated kinetic
values and to use the resulting correlation’s equation for the
design of a number of novel prodrugs [17].
For example, DFT and MM methods we have researched the
mechanisms for the intramolecular proton transfer in Kirby’s acet-
als and Bruice’s cyclization of dicarboxylic semiesters which led to
the design and synthesis of the following novel prodrugs: aza-
nucleosides prodrugs for the treatment for myelodysplastic syn-
dromes, tranexamic acid prodrugs for the treatment of hemor-
rhage conditions, dopamine prodrugs for Parrkinson’s disease,
atovaquone prodrugs as antimalarial agents, bitterless paraceta-
mol prodrugs as antipyretic and pain killer for pediatrics and
geriatrics, and prodrugs of the decongestant phenylephrine. In
the above-mentioned examples, the prodrug linker was bound to
the amine or hydroxyl group in the parent drug in such a way that
the drug-linker entity (prodrug) intraconverts upon an exposure to
the physiological environment such as stomach, intestine, and/or
blood circulation, with intramolecular reaction rates that are only
determined on the chemical structural features of the pharmaco-
logically inactive promoiety (linker) [18].
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